The drugmaker, which is reeling from the controversy over Vytorin and the ensuing drop in prescriptions, is closing plants and cutting 10 percent of its workforce of 55,000 in order to save up to $1.5 billion. The move also comes a few months after Schering-Plough bought Organon Biosciences and had already begun slashing jobs to reduce expenses by $500 million which, of course, means the latest problems contributed to the extra $1 billion in savings targeted.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments